Comparative Effectiveness of Tirzepatide Versus Semaglutide in Individuals With Heart Failure With Preserved Ejection Fraction

Active, not recruitingOBSERVATIONAL

Enrollment

28,118

Participants

Timeline

Start Date

January 14, 2025

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2025

Conditions

Diabetes Mellitus, Type 2HFpEF - Heart Failure With Preserved Ejection Fraction

Interventions

DRUG

Tirzepatide

New use of tirzepatide dispensing claim is used as the exposure.

DRUG

Semaglutide

New use of semaglutide dispensing claim is used as the reference.

Trial Locations (1)

Brigham and Women's Hospital, Boston

All Listed Sponsors

lead

Brigham and Women's Hospital

OTHER